PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
- 11 December 2013
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 5 (215), 215ra172
- https://doi.org/10.1126/scitranslmed.3006597
Abstract
T cell therapies have demonstrated long-term efficacy and curative potential for the treatment of some cancers. However, their use is limited by damage to bystander tissues, as seen in graft-versus-host disease after donor lymphocyte infusion, or “on-target, off-tumor” toxicities incurred in some engineered T cell therapies. Nonspecific immunosuppression and irreversible T cell elimination are currently the only means to control such deleterious responses, but at the cost of abrogating therapeutic benefits or causing secondary complications. On the basis of the physiological paradigm of immune inhibitory receptors, we designed antigen-specific inhibitory chimeric antigen receptors (iCARs) to preemptively constrain T cell responses. We demonstrate that CTLA-4– or PD-1–based iCARs can selectively limit cytokine secretion, cytotoxicity, and proliferation induced through the endogenous T cell receptor or an activating chimeric receptor. The initial effect of the iCAR is temporary, thus enabling T cells to function upon a subsequent encounter with the antigen recognized by their activating receptor. iCARs thus provide a dynamic, self-regulating safety switch to prevent, rather than treat, the consequences of inadequate T cell specificity.Keywords
This publication has 56 references indexed in Scilit:
- Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanomaBlood, 2013
- Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T CellsScience Translational Medicine, 2013
- The Basic Principles of Chimeric Antigen Receptor DesignCancer Discovery, 2013
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic LeukemiaScience Translational Medicine, 2013
- HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significanceOncogene, 2008
- OPCML Is a Broad Tumor Suppressor for Multiple Carcinomas and Lymphomas with Frequently Epigenetic InactivationPLOS ONE, 2008
- Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapyImmunological Reviews, 2008
- Human regulatory T cells: role in autoimmune disease and therapeutic opportunitiesImmunological Reviews, 2008
- The reverse stop-signal model for CTLA4 functionNature Reviews Immunology, 2008
- A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transferProceedings of the National Academy of Sciences of the United States of America, 2008